Andrew W. B. Craig

Andrew W. B. Craig

Auto-generated profile, based on publicly available information

Andrew W. B. Craig

Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1998 in Nature
Verified
Journal Article
Closed access
PDF file
ACAndrew W. B. Craig
Andrew W. B. Craig
AHAshkan Haghighat
Ashkan Haghighat
AYAnnie T. K. Yu
Annie T. K. Yu
NSNahum Sonenberg
Nahum Sonenberg

1 January 2001 in Molecular Cell
Verified
Journal Article
Closed access
KKKianoush Khaleghpour
Kianoush Khaleghpour
YSYuri V Svitkin
Yuri V Svitkin
ACAndrew W Craig
Andrew W Craig
CDChristine T DeMaria
Christine T DeMaria
RDRahul C Deo
Rahul C Deo
NSNahum Sonenberg
Nahum Sonenberg

7 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
MBMadison Black
Madison Black
IBIvraym B. Barsoum
Ivraym B. Barsoum
PTPeter Truesdell
Peter Truesdell
TCTiziana Cotechini
Tiziana Cotechini
SMShannyn K. Macdonald-Goodfellow
Shannyn K. Macdonald-Goodfellow
CGCharles H. Graham
Charles H. Graham
Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis

15 July 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MHManar Hammood
Manar Hammood
ACAndrew W. Craig
Andrew W. Craig
JLJeffrey Victor Leyton
Jeffrey Victor Leyton
Biologically-based therapies increasingly rely on the endocytic cycle of internalization and exocytosis of target receptors for cancer therapies. However, receptor trafficking pathways (endosomal sorting (recycling, lysosome localization) and lateral membrane movement) are often dysfunctional in cancer. Antibody-drug conjugates (ADCs) have revitalized the concept of targeted chemotherapy by coupling inhibitory antibodies to cytotoxic payloads. Significant advances in ADC technology and format, and target biology have hastened the FDA approval of nine ADCs (four since 2019). Although the links between aberrant endocytic machinery and cancer are emerging, the impact of dysregulated internalization processes of ADC targets and response rates or resistance have not been well studied. This is despite the reliance on ADC uptake and trafficking to lysosomes for linker cleavage and payload release. In this review, we describe what is known about all the target antigens for the currently approved ADCs. Specifically, internalization efficiency and relevant intracellular sorting activities are described for each receptor under normal processes, and when complexed to an ADC. In addition, we discuss aberrant endocytic processes that have been directly linked to preclinical ADC resistance mechanisms. The implications of endocytosis in regard to therapeutic effectiveness in the clinic are also described. Unexpectedly, information on endocytosis is scarce (absent for two receptors). Moreover, much of what is known about endocytosis is not in the context of receptor-ADC/antibody complexes. This review provides a deeper understanding of the pertinent principles of receptor endocytosis for the currently approved ADCs.

1 July 2004 in Journal of Cell Science
Verified
Journal Article
Closed access
GXGang Xu
Gang Xu
ACAndrew W. B. Craig
Andrew W. B. Craig
PGPeter Greer
Peter Greer
MMMatthew Miller
Matthew Miller
PAPanos Z. Anastasiadis
Panos Z. Anastasiadis
JBJanne Balsamo
Janne Balsamo
The function of Type 1, classic cadherins depends on their association with the actin cytoskeleton, a connection mediated by α- and β-catenin. The phosphorylation state of β-catenin is crucial for its association with cadherin and thus the association of cadherin with the cytoskeleton. We now show that the phosphorylation of β-catenin is regulated by the combined activities of the tyrosine kinase Fer and the tyrosine phosphatase PTP1B. Fer phosphorylates PTP1B at tyrosine 152, regulating its binding to cadherin and the continuous dephosphorylation of β-catenin at tyrosine 654. Fer interacts with cadherin indirectly, through p120ctn. We have mapped the interaction domains of Fer and p120ctn and peptides corresponding to these sequences release Fer from p120ctn in vitro and in live cells, resulting in loss of cadherin-associated PTP1B, an increase in the pool of tyrosine phosphorylated β-catenin and loss of cadherin adhesion function. The effect of the peptides is lost when a β-catenin mutant with a substitution at tyrosine 654 is introduced into cells. Thus, Fer phosphorylates PTP1B at tyrosine 152 enabling it to bind to the cytoplasmic domain of cadherin, where it maintains β-catenin in a dephosphorylated state. Cultured fibroblasts from mouse embryos targeted with a kinase-inactivating ferD743R mutation have lost cadherin-associated PTP1B and β-catenin, as well as localization of cadherin and β-catenin in areas of cell-cell contacts. Expression of wild-type Fer or culture in epidermal growth factor restores the cadherin complex and localization at cell-cell contacts.

8 March 2004 in Oncogene
Verified
Journal Article
Closed access
AVAdina Vultur
Adina Vultur
JCJun Cao
Jun Cao
RARozanne Arulanandam
Rozanne Arulanandam
JTJames Turkson
James Turkson
RJRichard Jove
Richard Jove
LRLeda Raptis
Leda Raptis